Shanghai Financial Statements From 2010 to 2025

SFOSFDelisted Stock  USD 2.67  0.00  0.00%   
Shanghai Fosun's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Shanghai Fosun's valuation are provided below:
Shanghai Fosun Pharmaceutical does not presently have any fundamental trend indicators for analysis.
Check Shanghai Fosun financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shanghai Fosun's main balance sheet or income statement drivers, such as , as well as many indicators such as . Shanghai financial statements analysis is a perfect complement when working with Shanghai Fosun Valuation or Volatility modules.
  
This module can also supplement various Shanghai Fosun Technical models . Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Shanghai Fosun Pharmaceutical Company Return On Equity Analysis

Shanghai Fosun's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Shanghai Fosun Return On Equity

    
  0.0756  
Most of Shanghai Fosun's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Shanghai Fosun Pharmaceutical has a Return On Equity of 0.0756. This is 100.32% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 124.39% lower than that of the firm.

Shanghai Fosun Pharm Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Fosun's current stock value. Our valuation model uses many indicators to compare Shanghai Fosun value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Fosun competition to find correlations between indicators driving Shanghai Fosun's intrinsic value. More Info.
Shanghai Fosun Pharmaceutical is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about  0.27  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Shanghai Fosun Pharmaceutical is roughly  3.71 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Shanghai Fosun's earnings, one of the primary drivers of an investment's value.

About Shanghai Fosun Financial Statements

Shanghai Fosun stakeholders use historical fundamental indicators, such as Shanghai Fosun's revenue or net income, to determine how well the company is positioned to perform in the future. Although Shanghai Fosun investors may analyze each financial statement separately, they are all interrelated. For example, changes in Shanghai Fosun's assets and liabilities are reflected in the revenues and expenses on Shanghai Fosun's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Shanghai Fosun Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Shanghai Fosun Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. Shanghai Fosun Pharmaceutical Co., Ltd. was founded in 1994 and is based in Shanghai, China. Shanghai Fosun operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 36604 people.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Shanghai Pink Sheet

If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Directory
Find actively traded commodities issued by global exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges